The Most Favored Nation (MFN) drug pricing policy is gaining momentum in the United States. While the policy’s breadth of ...
In recent months – as credit spreads have continued to widen – sponsors, borrowers and lenders alike have frequently found themselves combing through their loan documents to check the scope of the ...
Half of the experts, members of the Cornell Health Policy Insight Panel, indicated MFN pricing would substantially reduce net US drug prices, while half disagreed or were uncertain about the effects.
The MFN executive order introduces uncertainty in pharma pricing strategies, necessitating careful risk assessment and mitigation planning for product launches. Companies should evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results